TOMOCUBE, Inc.
KKRX:47596030,400.00
KRW
-700.00
(-2.25%)
ISIN
KR7475960001
Return %
Stock
S&P 500
1Y
-24.94
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yong-Geun Park
- Full Time Employees
- 76
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Daejeon South Korea
- IPO Date
- Nov 7, 2024
- Website
- tomocube.com
- Similar Companies
- Business
- TOMOCUBE, Inc. is a South Korea-based biotechnology and precision optical imaging company that specializes in the development, manufacture, and commercialization of holotomography (HT) microscopy systems and artificial intelligence-driven quantitative live-cell analysis solutions. Founded in 2015 and headquartered in Daejeon, South Korea, the company operates in the life science instruments, bio-imaging, and medical diagnostics sectors. TOMOCUBE utilizes optical diffraction tomography and quantitative phase imaging technologies to provide label-free, non-invasive, high-resolution three-dimensional (3D) and four-dimensional (4D) imaging of live biological cells and tissues without requiring chemical fixation, staining, or fluorescent labeling. The company's core product portfolio encompasses advanced holotomographic imaging systems and proprietary software, including: the HT-X1 system, a high-throughput 3D holotomography platform designed for multi-well plate automation, live-cell kinetic monitoring, and large-scale organoid or spheroid screening; the HT-2 series, which integrates holotomography with 3D correlative fluorescence imaging to enable multimodal intracellular research; the HT-1 series, offering foundational 3D holographic refractive index microscopy for single-cell biophysical characterization; the TomoStudio and TomoAnalysis software suites, providing real-time 3D volumetric reconstruction, automated cellular segmentation, optical refractive index measurement, and quantitative morphological and biophysical analysis; and specialized live-cell incubation chambers, sample mounting systems, and consumable accessories engineered for long-term kinetic cell culture experiments. These solutions serve academic research institutions, biopharmaceutical corporations, biotechnology developers, and contract research organizations engaged in cell and gene therapy, regenerative medicine, immuno-oncology, infectious disease research, drug discovery, and toxicology screening. In recent major developments, TOMOCUBE completed its initial public offering on the KOSDAQ market of the Korea Exchange under the ticker symbol KRX:475960 in November 2024 to accelerate global commercial expansion and scale production capabilities. The company has actively expanded its international distribution network across North America, Europe, and the Asia-Pacific region, establishing strategic commercial alliances with regional life science distributors and academic medical centers. In addition, TOMOCUBE has expanded its technological footprint through the advancement of AI-powered automated phenotypic screening tools for 3D organoid models and cell therapy quality control, reinforcing its presence in high-throughput biopharmaceutical drug discovery and clinical translational research.